72 results about "Bupivacaine" patented technology

Provided is a pharmaceutical composition for permeabilizing fetal membranes including an active ingredient having a log K in the range of 2 to 4, where K is the octanol / water partition coefficient. The active ingredient may be, for example, bupivacaine, sodium lauryl sulfate or oleic acid. Further provided is a system for transfetal membrane transport. The system includes a probe unit adapted for insertion into a female reproductive tract and releasing a substance onto fetal membranes that permeabilizes the membranes. The system is also configured to apply ultrasound radiation to the fetal membranes to further increase the membrane permeability.

Disclosed are bupivacaine transdermal delivery systems, and related methods.

The invention relates to a local anesthetic sustained-release preparation with phospholipid-mixed solvent-oil as a carrier, and a preparation method thereof. The sustained-release preparation is prepared from local anesthetic as an active ingredient and a mixture of phospholipid-mixed solvent-oil as a sustained-release drug delivery system, and selectively is prepared from an antioxidant, whereinthe local anesthetic is selected from one of bupivacaine or ropivacaine free base or a mixture thereof; the mixed solvent is a mixture of benzyl benzoate and one or two of benzyl alcohol, ethanol; theantioxidant is vitamin E acetate, lipoic acid and the like; in the phospholipid-mixed solvent-oil mixture, the content of phospholipid does not exceed 50%, the content of benzyl benzoate does not exceed 10%, and the rest is oil.

Dermal compositions comprising topical formulations of bupivacaine or ropivacaine, characterized by effective dermal absorption and long duration of dermal anesthetic activity, and intended for use in patients suffering from pruritus and dermal pain, including neuropathic pain, are provided. Compositions containing both bupivacaine and capsaicin are provided. Methods of alleviating pain by the topically administration of these compounds are also provided.

Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.

The invention relates to bis-[6-oxa-(2-carboxylbenzenesulfonyl-butanedioic acid 1,4 monoester-4)-beta-cyclodextrin, a preparation method and application thereof as chiral selective agent in high performance capillary electrophoresis (HPCE), namely being prepared into a chiral electrophoresis column and a mobile phase chiral additive for detachment of chiral substances. The molecular formula of the bis-[6-oxa-(2-carboxylbenzenesulfonyl-butanedioic acid 1,4 monoester-4)-beta-cyclodextrin is determined to be C64H84O49S2; beta-CD-B2 is used as the HPCE mobile phase chiral additive to separate chiral substances of phenylglycinol, anisodamine, isoprenaline and propafenone to realize baseline separation; beta-CD-B2 is used for preparing a chiral HPCE column to separate chlortrimeton, bupivacaine, procaine, atenolol, anisodamine, propafenone, lobeline and other chiral substances to realize the baseline separation. Therefore, a novel HPCE quantitative measurement method for a single enantiomerof various chiral substances can be established.

The invention belongs to the field of medical examination and relates to a method capable of synchronously determining the concentrations of a plurality of local anesthetic drugs in human plasma. The method adopts a plasma cholineesterase inhibitor to inhibit the activity of plasma cholinesterase under ice bath condition below 3 DEG C, which controls the hydrolysis of totokaine and assures the accuracy of the method; by utilizing characteristics that lidocaine, ropivacaine and bupivacaine have stronger characteristic of ultraviolet absorption at wavelength of 210nm, and procaine and the totokaine have stronger characteristic of ultraviolet absorption at wavelength of 290nm, an ultraviolet dual-wavelength method is used to detect after the separation of an acid mobile phase at a chromatographic column; and the method can ensure that the sensitivity of synchronous determination of the local anesthetic drugs is greatly improved. The method has less sampling from samples and simple, quickand sensitive pretreatment, does not need expensive equipment or reagents, has short analysis period and low cost, and is suitable for the monitoring of clinical conventional blood concentration of aplurality of drugs.

A medical device, comprising: an array of microneedles, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting of tetracaine, ropivacaine, bupivacaine, procaine and a combination thereof; wherein the local anesthetic is present in an amount of at least 1 wt-% based upon total weight of solids in the coating, and wherein the local anesthetic and dose-extending component are in a non-eutectic weight ratio; a medical device, comprising an array of dissolvable microneedles, the microneedles comprising: a dissolvable matrix material; at least 1 wt-% of a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting of tetracaine, ropivacaine, bupivacaine, procaine and a combination thereof; wherein the local anesthetic and dose-extending component are in a non-eutectic weight ratio, and wherein wt-% is based upon total weight of solids in all portions of the dissolvable microneedles which contain the local anesthetic; a method of extending a topically delivered local anesthetic dose in mammalian tissue using the devices; and methods of making the devices are provided.

The invention belongs to a synthesis method of bupivacaine. The method comprises: adding 2 piperidinecarboxylicacid into aqueous alkali, dropwise adding Cbz and alkaline water, after finishing dropwise adding at normal temperature, reacting for 12 hours, after reaction, extracting with diethyl ether, washing a water layer to be weak-acid with 18% of diluted hydrochloric acid, extracting with the diethyl ether again, combining an diethyl ether layer, drying and filtering, and concentrating to obtain a dried product; adding the dried product into a DMF solvent, then adding a catalyst for reaction for 1 hour at normal temperature, then adding 2,6-dimethylaniline, reacting for 18hours at normal temperature, adding water and ethyl acetate for washing, taking an organic layer, drying and filtering, and concentrating to obtain a dried concentrated product; adding the dried concentrated product into a solvent, then adding a catalyst, pressurizing and introducing hydrogen, filtering after reaction and concentrating to obtain a dried product; adding the product in the above step into a solvent, dropwise adding bromo-n-butane at normal temperature, after dropwise adding, rising temperature to 80 DEG C for reacting for 12 hours, adding diluted hydrochloric acid, slowing cooling to normal temperature, and crystallizing, filtering and drying to obtain the product. The synthesis method has the advantages of higher yield, smaller pollution and low equipment requirement.

The invention relates to the technical field of pharmaceutical preparations, and provides a preparation method of biodegradable bupivacaine microspheres with high drug loading capacity. Bupivacaine microspheres entrapping free alkali are prepared by utilizing biodegradable high-molecular-weight polylactic acid as a carrier material according to an emulsified solvent evaporation method. The frozen-dried bupivacaine microspheres are dispersed in a medium for injection so as to be subjected to local injection administration, and is used for postoperative analgesia or is used for relieving local pains; the weight ratio of bupivacaine to the carrier material is (75:25) to (85:15), the drug loading capacity of the bupivacaine in the microspheres is not less than 60%, and medicaments can be completely released within 5-7 days.

One embodiment of the present invention is a method for reducing pain using a multi chamber pump to separately administer multiple drugs. For example, one chamber may contain an omega conopeptide, such as ziconotide, and the other chamber or chambers may contain one or more other drugs, which may include of morphine, hydromorphone, fentanyl, sufentanil, bupivacaine, baclofen, clonidine, and buprenorphine, or their pharmaceutically acceptable salts thereof. Other applications of the present invention include methods for treating severe chronic pain due to cancer, failed back syndrome, CRPS, neuropathic pain, mixed neuropathic and nociceptive pain.

The invention discloses a medicine composition with the functions of narcotizing in an operation and alleviating pain after the operation. The medicine composition comprises tetracaine, bupivacaine, mastic, rhizoma cyperi, girald daphne bark, white peony root and menthol. The medicine composition is added with conventional auxiliary materials in pharmacy according to a conventional process to prepare a clinically acceptable medicament form. The medicine composition is a medicine for injecting and narcotizing in the operation and alleviating pain in a long acting way after the operation and is already applied to clinic successfully throughout the years. The medicine composition can enable the surgical field to be clear, can also avoid pain, sagging distention, frequent defecation and uroschesis caused by the operation, can loosen the anal canal fully and is convenient for the surgical operation.

The invention discloses an amide compound, a preparation method and application thereof, and particularly provides a compound as shown in a formula (I), or a salt thereof, or an isotope replacement form thereof, or an optical isomer thereof, or a solvate thereof, or a crystal form thereof, or a prodrug thereof. According to the invention, the local anesthetic effect duration of the compound provided by the invention is obviously longer than that of a contrast drug bupivacaine; and compared with bupivacaine, the compound provided by the invention is higher in titer and better in safety, can bedecomposed and removed from plasma more quickly, and has a very good application prospect in preparation of local anesthetic drugs or local analgesic drugs.

The invention relates to a sustained-release analgesic drug, which is microsphere of a topical anesthesia agent. The topical anesthesia agent comprises lidocaine, tetracaine, bupivacaine, oxybuprocaine and procaine. The sustained-release microsphere provided by the invention can be prepared into a sterile microsphere injection, a powder, a spray, a tablet, a capsule, a lozenge, a soft capsule, a pill, a syrup, an external ointment, an emulsion, a bandage, a binder and a gauze. The sustained-release microsphere can be prepared by a multiple double emulsion method, a non-aqueous method, a low temperature spray extraction method or a phase coacervation method. The sustained-release analgesic drug provided by the invention can be used for pain killing of skin wounds with small area, such as cuts, abrasions and burns, and operation wounds.

The invention belongs to the technical field of preparations, and specifically relates to a high-concentration bupivacaine multivesicular liposome as well as a preparation method and a liquid distribution system thereof. The liquid distribution system comprises a main liquid distribution tank, a plurality of auxiliary liquid distribution tanks which are arranged in parallel on the main liquid distribution tank, and a heating apparatus and an air exhaust apparatus which are respectively located on the main liquid distribution tank, wherein the heating apparatus is suitable for heating test liquid in the main liquid distribution tank and the air exhaust apparatus is suitable for maintaining vacuum degree in the main liquid distribution tank, thereby allowing extraction of volatile organic solvents from the test liquid; and thus, nitrogen generator and gas sterile filtration are not required while sterility control of gas is not needed, so that, difficulty of control of aseptic process isreduced with aseptic environment in liquid distribution process improved. Therefore, the liquid distribution system is suitable for industrial production.

The invention relates to a method for enriching a piperidine-2-formanilide optically active compound. The method comprises the following steps of: mixing R type ropivacaine and bupivacaine or an intermediate thereof with an inert solvent, an initiating agent and mercaptan and carrying out a racemization reaction to obtain a reaction solution containing RS configuration ropivacaine, bupivacaine orthe intermediate thereof; adding acid to the reaction solution to carrying out salifying reaction, bleaching and extracting through an organic solvent, drying and dewatering an organic phase, and carrying out spinning evaporating to obtain racemized ropivacaine, bupivacaine or the intermediate solid thereof; adding the obtained solid salt to acetone to separate out DBTA (Dibenzoyl Tartaric Acid) salt which is an S type enantiomer, wherein at the moment, a large quantity of white precipitates are generated in the solution, and bleaching to obtain white solid; and dissolving the solid into alkali, and then bleaching to obtain an enriched piperidine-2-formanilide optically active compound. The method provided by the invention shortens the time and reduces the temperature of the racemization reaction, reduces pollution to environment, caused by wastes and improves the production efficiency.

Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.

According to one aspect, the fibers of a muscle to be shortened or lengthened are exposed to a local anesthetic drug such as bupivacaine. The concentration and volume of the local anesthetic drug are sufficient to causes the muscle fibers to be damaged by the myotoxicity of the drug. The muscle is then kept at a different length, shorter or longer, during the ensuing period of muscle fiber regeneration, resulting in a shortened or lengthened muscle. In one embodiment, the shortened length of the treated muscle improved the position and the movement of the eye to which it was attached.

The present invention relates to compositions comprising a lipophilic local anaesthetic, preferably bupivacaine or a pharmaceutically active salt thereof, which are formulated for local administration to the mouth or throat of a subject. The compositions are useful in the treatment or alleviation of pain, burning or xerostomia of the oral cavity, pharynx, oral mucosa and pharyngeal mucosa or for use in providing local anesthesia of the oral cavity, pharynx, oral mucosa and pharyngeal mucosa. In particular in the treatment of pain, burning or xerostomia, which is caused by a disease such as oral mucositis, Burning Mouth Syndrome, Sjogren's syndrome, xerostomia, periodontitis, toothache, tonsillectomy, throat infection or mononucleosis, canker sores and aphthous stomatitis.

The invention discloses a preparation method of bupivacaine multivesicular liposome and a bupivacaine multivesicular liposome preparation, and relates to the field of bupivacaine medicinal preparations. The preparation method of the bupivacaine multivesicular liposome comprises the following steps: adding a neutral fat into a preemulsion formed from an organic solvent-containing oil phase and a bupivacaine-containing first water phase to obtain a first solution for forming a compound emulsion. Compared with the conventional preparation method of the bupivacaine multivesicular liposome, the preparation method provided by the invention has the advantages as follows: through the step of adding the neutral fat into the preemulsion formed from the organic solvent-containing oil phase and the bupivacaine-containing first water phase, the problem of breakage of the multivesicular liposome in the subsequent organic solvent removing step can be overcome, so that the prepared multivesicular liposome is round in shape and basically free of phospholipid fragments, and thus the long-acting slow-release effect of a bupivacaine medicine is improved.

What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a triglyceride of ricinoleic acid, a gelling agent, bupivacaine and, optionally, a corticosteroid, an analgesic, or an anti-inflammatory agent.

The invention relates to the field of medicines, and particularly relates to a pharmaceutical composition which has anesthetic action in operation. The composition is prepared from 1.0-3.0mg of bupivacaine, 1-5mu g of sufentanil, 15-30mu g of tetrahydropalmatine, 15-30 mu g of indometacin and 0.1-0.5mg of ropivacaine. The anesthetic composition is preferably prepared from 3.0mg of bupivacaine, 3mu g of sufentanil, 20mu g of tetrahydropalmatine, 20mu g of indometacin and 0.3mg of ropivacaine.

A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethyl-ene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle or hydrophobic active principle such as medroxyprogesterone acetate, levonorgestrel, cyclosporine, progesterone or bupivacaine is disclosed.

The invention discloses a skin topical preparation containing bupivacaine or pharmaceutical salt thereof, and provides an external preparation for local administration. The preparation contains active pharmaceutical ingredients, a pressure-sensitive adhesive binder, a diluent and other pharmaceutically acceptable excipients. The adopted pressure-sensitive adhesive binder is an acrylic acid pressure-sensitive adhesive containing hydroxyl, or a silicone pressure-sensitive adhesive or a mixture of the two. The pressure-sensitive adhesive enables the active pharmaceutical ingredients to exist stably and does not chemically react with the active pharmaceutical ingredients, so that drug stability is improved, and clinical application of the preparation is safer and more reliable. Meanwhile, the pressure-sensitive adhesive material can effectively avoid crystallization of a patch, and can also control the viscosity of the patch on the basis of certain content, so that the patch does not fall off easily in use, skin can not be injured when the patch is peeled off, no residue is left on skin, pollution is avoided, and great convenience is brought to patients in use.

The invention discloses a calf beef producing property improving method, which comprises the following steps: 1) injecting expressive plasmid of growth hormone releasing factor gene in the calf musculus semitendinosus positing, 2) setting the fitful agent quantity at 5-7mg per calf, 3) adopting the density of injection dilution liquid of expressive plasmid at 0.25% bupivacaine PSS, 4) improving beef producing property without influencing quality and safety.